In this week’s video, Dr. Durie discusses if minimal residual disease (MRD) testing should be routinely performed, and the potential use for MRD testing in the near future.
The BOTTOM LINE:
MRD testing will hopefully be a surrogate marker in clinical trials soon. However, at this time, routine MRD testing is not currently recommended.
Please subscribe to our channel!
Subscribe to International Myeloma Foundation: [ Ссылка ]
Visit our website at: [ Ссылка ]
Find us online:
Facebook: [ Ссылка ]
Google+: [ Ссылка ]
IMF on twitter: @IMFMyeloma ([ Ссылка ])
Dr. Durie on twitter: @BrianDurieMD ([ Ссылка ])
Support the IMF! [ Ссылка ]
Category
Nonprofits & Activism
License
Standard YouTube License
